Explore 3 Stock Ideas & Industry Insights Download Free Report

News

nCino, Inc. (NASDAQ: NCNO) Reports Q2FY26 Results; Subscription Revenue Growth Continues

nCino, Inc. (NASDAQ: NCNO) announced financial results for the second quarter of fiscal year 2026, ended July 31, 2025, reporting continued expansion in subscription revenue alongside improvements in non-GAAP profitability. Total revenue for the quarter was USD148.8 million, up 12% from USD132.4 million in …

Team Kalkine | 26 August 2025

Domo (NASDAQ: DOMO) Expands BigQuery Cloud Integration with New Governance Tools

Domo (NASDAQ: DOMO), an AI and data products company, announced a set of enhancements to its existing integration with Google Cloud’s BigQuery aimed at improving governance, user experience, and multi-user collaboration for joint customers. The updates focus on administration controls, clearer configuration workflows, and …

Team Kalkine | 26 August 2025

MongoDB (NASDAQ: MDB) Reports Q2FY26 Results — Atlas Revenue Accelerates

MongoDB, Inc. (NASDAQ: MDB) reported results for the second quarter ended July 31, 2025, with revenue expansion led by subscription sales and continued margin improvement on a non-GAAP basis. Total revenue for the quarter was $591.4 million, up 24% from the comparable period a …

Team Kalkine | 26 August 2025

Broadcom (NASDAQ: AVGO) and Walmart (NYSE: WMT) Partner on Private Cloud and Edge

Broadcom Inc. (NASDAQ: AVGO) and Walmart Inc. (NYSE: WMT) announced a strategic collaboration at VMware Explore 2025 to deliver a modern private cloud and edge environment across Walmart’s global operations. Broadcom has been named a strategic vendor for virtualization software solutions and will leverage …

Team Kalkine | 26 August 2025

MicroCloud Hologram Inc. (NASDAQ: HOLO) Forecasts H1 2025 Return to Profitability

MicroCloud Hologram Inc. (NASDAQ: HOLO) said it expects a material year-over-year turnaround to profitability for the first half of 2025, projecting net profit in excess of RMB 230 million versus a reported net loss of roughly RMB 120 million in the same period last …

Team Kalkine | 26 August 2025

Immuron Limited (NASDAQ: IMRN) Launches InvestorHub Partnership

Immuron Limited (ASX: IMC; NASDAQ: IMRN) has entered a strategic partnership with InvestorHub, a direct-to-investor engagement software provider, as part of a broader effort to streamline communications with shareholders and the investment community. The agreement establishes an interactive investor hub designed to consolidate corporate …

Team Kalkine | 26 August 2025

Stocks Slip, Commodities Retreat, and Political Uncertainty Drives Safe-Haven Demand

Index Update:On Monday, the Dow fell 0.77%, the S&P 500 dropped 0.43%, and the Nasdaq slipped 0.22%, with nine of 11 S&P sectors lower, led by consumer staples, healthcare, and utilities. Losses followed profit-taking after Friday’s rally on Fed rate-cut signals, while Interactive Brokers …

Team Kalkine | 26 August 2025

EHang Holdings (NASDAQ:EH) Q2 2025 — Revenues Jump as Commercial Trials Expand

EHang reported a sharp quarter of topline growth and operational milestones as it pushes commercialisation of its EH216 series. The company posted Q2 2025 revenue of RMB147.2 million (US$20.5 million), a 44.2% increase year-over-year and a 464.0% jump quarter-over-quarter, and reported a gross margin …

Team Kalkine | 26 August 2025

Evoke Pharma (NASDAQ:EVOK) Expands GIMOTI Access via Omnicell and Brentwood Deals

Evoke Pharma announced a set of distribution agreements intended to materially broaden patient access to GIMOTI® nasal spray, the only FDA-approved intranasal treatment for adults with acute and recurrent diabetic gastroparesis. The company said strategic arrangements with Omnicell (NASDAQ: OMCL) and Brentwood Pharmacy will …

Team Kalkine | 26 August 2025

Marker Therapeutics (NASDAQ:MRKR) Posts 66% ORR in Phase 1 APOLLO Study

Marker Therapeutics reported encouraging early efficacy and tolerability data from its Phase 1 APOLLO study of MT-601, a Multi-Antigen Recognizing T cell product, in relapsed lymphoma. The trial enrolled 24 B-cell lymphoma patients across seven U.S. clinical sites with dose levels spanning 100×10^6 to …

Team Kalkine | 26 August 2025
Support

Hi! How can we help you today?

Loading…